Wei Luo
Adult Health · Ann Arbor, MINPI 1528659836
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 11.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,516, more than ten times the $126 reported in 2021. Among adult health clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 40 payments — averaging $91.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$428
- Amgen$244
- Gilead$234
- Teva Pharmaceuticals USA, Inc.$216
- AbbVie$209
- GSK$206
- plus $2K from 19 others
What the payments were for
- Food & beverage$3,53397%
- Entertainment$1263%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 4 | $428 |
| Amgen | 2 | $244 |
| Gilead | 2 | $234 |
| Teva Pharmaceuticals USA, Inc. | 2 | $216 |
| AbbVie | 2 | $209 |
| GSK | 2 | $206 |
| Alnylam Pharmaceuticals Inc. | 2 | $195 |
| Pfizer | 3 | $165 |
| E.r. Squibb & Sons, L.L.C. | 2 | $160 |
| Novo Nordisk | 2 | $151 |
| Medtronic | 2 | $144 |
| Kestra Medical Technology Services, Inc. | 1 | $137 |
| Scynexis, Inc. | 1 | $126 |
| Lundbeck LLC | 1 | $125 |
| Optinose US, Inc. | 2 | $124 |
| Jazz Pharmaceuticals Inc. | 1 | $122 |
| Sanofi | 1 | $116 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $101 |
| Axsome Therapeutics, Inc. | 1 | $95 |
| Corcept Therapeutics | 1 | $93 |
| Bayer | 1 | $73 |
| Boston Scientific | 1 | $66 |
| Neurocrine Biosciences, Inc. | 1 | $49 |
| Molnlycke Health Care US, LLC | 1 | $46 |
| Dexcom, Inc. | 1 | $35 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,659 in reported general payments places this provider in the 90th percentile of 527 adult health providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 236 | $66,628 |
| JanuviaSitagliptin Phosphate | 41 | $13,639 |
| RestasisCyclosporine | 30 | $12,430 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $11,310 |
| NuedextaDextromethorphan Hbr/Quinidine | 14 | $10,601 |
| FarxigaDapagliflozin Propanediol | 35 | $10,223 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $9,698 |
| XareltoRivaroxaban | 30 | $7,905 |
| JardianceEmpagliflozin | 25 | $7,904 |
| Spiriva HandihalerTiotropium Bromide | 13 | $7,082 |
| TradjentaLinagliptin | 26 | $6,830 |
| Atorvastatin Calcium | 322 | $6,490 |
| Arnuity ElliptaFluticasone Furoate | 21 | $5,570 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $5,535 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 29 | $5,251 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $165 | $66,628236 claims |
| GSKBreo Ellipta, Arnuity Ellipta | $206 | $16,88047 claims |
| AstraZenecaFarxiga, Symbicort | $428 | $12,69846 claims |
| AbbVieRestasis | $209 | $12,43030 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 527 adult health providers in Michigan.
Other adult health in Ann Arbor
- Susanne QuallichAnn Arbor$42K
- Deniene KingAnn Arbor$14K
- Danmar DomingoAnn Arbor$5K
- Jacqueline BrewerSterling Heights$138K
- Linda Morris McCoyGrand Rapids$59K
- Sarita RaoCanton$51K
- Nancy BermanSouthfield$39K
- Michelle MillerQuincy$24K
- Adama JohnsonEastpointe$14K
- Bridget BonelloWyandotte$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.